Drug Profile
Testosterone undecanoate - Marius Pharmaceuticals
Alternative Names: KYZATREX; MRS 2012; SOV-2012-F1; T-replacement therapy - MariusLatest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator SOV Therapeutics
- Developer Marius Pharmaceuticals
- Class Anabolic steroids; Androstenols; Hormonal replacements; Small molecules; Testosterone congeners
- Mechanism of Action Testosterone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Hypogonadism
Most Recent Events
- 11 Apr 2024 Final adverse events and efficacy data from a phase III MRS-TU-2019EXT trial in Hypogonadism released by Marius Pharmaceuticals
- 12 Mar 2024 Launched for Hypogonadism in USA (PO)
- 16 Oct 2023 San Diego Sexual Medicine plans a phase II trial for Hypogonadism in USA (PO), in December 2023 (NCT06082817)